Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
134.89
-2.17 (-1.58%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
54
55
Next >
Weight-Loss Giant Novo Nordisk Tumbles To 200-Day Average Support: 'Weakness Could Be Buying Opportunity,' Analyst Says
August 07, 2024
Shares of Novo Nordisk are down 6% after Q2 results fell short of expectations; weight-loss drug sales disappoint.
Via
Benzinga
Ozempic-Maker Novo Nordisk Reveals Patients Stay On Wegovy Weight-Loss Drug For 6 Months Due To Low Availability
August 07, 2024
Via
Benzinga
Novo Nordisk Slumps On Second-Quarter Miss, Light Ozempic, Wegovy Sales
August 07, 2024
The company, however, hiked its sales outlook for the year.
Via
Investor's Business Daily
NVO Stock Earnings: Novo Nordisk Misses EPS, Misses Revenue for Q2 2024
August 07, 2024
NVO stock results show that Novo Nordisk missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
August 07, 2024
Novo Nordisk stock has surged thanks to booming sales of Ozempic and Wegovy.
Via
The Motley Fool
Novo Nordisk Tumbles 3% In Wednesday Premarket: What's Causing 'Miracle' Weight Loss Drug Ozempic Maker's Stock Slide?
August 07, 2024
The dip in Novo Nordisk's shares comes despite deep-pocketed investors were adopting a bullish approach.
Via
Benzinga
Novo Nordisk Unusual Options Activity For August 06
August 06, 2024
Via
Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
August 02, 2024
Via
Benzinga
Smart Money Is Betting Big In NVO Options
July 31, 2024
Via
Benzinga
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
August 05, 2024
Eli Lilly's Zepbound and Novo Nordisk's Wegovy face supply shortages, influencing doctors' prescribing habits. Both companies are investing heavily to meet demand in the lucrative U.S. market.
Via
Benzinga
After Ozempic And Botox, Hollywood Is Going Gaga Over This New Anti-Aging Supplement
August 05, 2024
This trend is gaining momentum although its effectiveness is yet to be determined.
Via
Benzinga
3 Unstoppable Stocks to Buy in August
August 03, 2024
It's not hard to envision how all three of these stocks can deliver exceptional growth.
Via
The Motley Fool
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
August 03, 2024
These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market.
Via
The Motley Fool
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
August 02, 2024
Psychologists warn of increased eating disorders linked to popular GLP-1 weight loss drugs like Wegovy and Zepbound. Experts urge better screening and research to address potential risks.
Via
Benzinga
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
August 02, 2024
Hims & Hers stock has been surging since May, but has its valuation gotten too rich?
Via
The Motley Fool
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
August 02, 2024
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users.
Via
Investor's Business Daily
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
August 02, 2024
The innovative biotech is looking for its next blockbuster.
Via
The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth.
Via
The Motley Fool
Why Eli Lilly Stock Trounced the Market on Thursday
August 01, 2024
What's good for Zepbound is good for the company, it seems.
Via
The Motley Fool
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
August 01, 2024
Anti-obesity therapeutics are all the rage and for good reason. Investors seeking to profit should consider these weight loss stocks.
Via
InvestorPlace
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
August 01, 2024
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth.
Via
The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
August 01, 2024
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term.
Via
The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
July 31, 2024
Investors should give consideration to taking a position in one of these top stocks to buy that are flashing strong growth signals.
Via
InvestorPlace
FDA Warns Of Overdose Risks With Compounded Wegovy, Ozempic Injections
July 30, 2024
FDA reports hospitalizations due to overdoses from compounded semaglutide products. Patients and health care providers miscalculate doses, leading to serious adverse events. The FDA advises proper...
Via
Benzinga
Exposures
Product Safety
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
July 30, 2024
Liraglutide shows promise in slowing cognitive decline in Alzheimer's patients, reducing brain volume loss and offering neuroprotective benefits, according to a Phase 2b clinical trial presented at...
Via
Benzinga
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
July 30, 2024
A study finds smokers with diabetes on Ozempic have fewer smoking-related medical interactions and interventions compared to those on other diabetes drugs. Research suggests potential for semaglutide...
Via
Benzinga
NYSE:NVO stands out as a growth opportunity that won't break the bank.
July 30, 2024
Investors should take note ofNOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced.
Via
Chartmill
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
July 30, 2024
DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now.
Via
The Motley Fool
3 Overlooked Stocks Poised for a Breakout Very Soon
July 29, 2024
Discover three overlooked breakout stocks with solid growth prospects, perfect for enhancing your investment portfolio.
Via
InvestorPlace
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
July 29, 2024
There's reason to believe that one of these two players will eventually win.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.